辽宁医学院学报
遼寧醫學院學報
료녕의학원학보
JOURNAL OF LIAONING MEDICAL UNIVERSITY
2014年
2期
12-14
,共3页
布地奈德福莫特罗%孟鲁司特%支气管哮喘%肺功能
佈地奈德福莫特囉%孟魯司特%支氣管哮喘%肺功能
포지내덕복막특라%맹로사특%지기관효천%폐공능
Budesonide/Fomoterol%Montelukast%bronchial asthma%lung function
目的：布地奈德福莫特罗干粉吸入剂联合孟鲁司特对中重度支气管哮喘肺功能的影响。方法选取我院85例中重度支气管哮喘，随机分为观察组45例，对照组40例。两组患者出现症状时使用短效支气管舒张剂缓解症状，对照组给予布地奈德/福莫特罗干粉吸入剂（160μg/4.5μg/吸，阿斯利康公司，早晚各1吸），观察组在对照组基础上口服孟鲁司特（10 mg，默沙东公司，1天1片）治疗，疗程12 w，比较两组治疗前、治疗后4、8、12 w的临床控制效果和肺功能的变化。结果治疗前，两组ACT评分和基本控制率无统计学差异（ P均＞0.05），治疗后4 w和8 w后，观察组的哮喘症状基本控制率分别为91.11％和93.33％， ACT评分分别为23.17±4.87和25.31±3.61，均显著高于对照组，两组比较具有统计学差异（ P均＜0.05），而治疗12周后，两组哮喘控制率和ACT评分无统计学差异（ P均＞0.05）；两组患者治疗疗程结束时，肺功能指标FEV1、 FEV1％和PEF％均明显改善，与治疗前比较差异具有统计学意义（ P均＞0.05），但两组间比较均无统计学的差异（ P＞0.05）。结论布地奈德福莫特罗干粉吸入剂与孟鲁司特可在早期迅速控制哮喘症状，改善病情，降低复发率，两药联合使用具有独特的优越性。
目的：佈地奈德福莫特囉榦粉吸入劑聯閤孟魯司特對中重度支氣管哮喘肺功能的影響。方法選取我院85例中重度支氣管哮喘，隨機分為觀察組45例，對照組40例。兩組患者齣現癥狀時使用短效支氣管舒張劑緩解癥狀，對照組給予佈地奈德/福莫特囉榦粉吸入劑（160μg/4.5μg/吸，阿斯利康公司，早晚各1吸），觀察組在對照組基礎上口服孟魯司特（10 mg，默沙東公司，1天1片）治療，療程12 w，比較兩組治療前、治療後4、8、12 w的臨床控製效果和肺功能的變化。結果治療前，兩組ACT評分和基本控製率無統計學差異（ P均＞0.05），治療後4 w和8 w後，觀察組的哮喘癥狀基本控製率分彆為91.11％和93.33％， ACT評分分彆為23.17±4.87和25.31±3.61，均顯著高于對照組，兩組比較具有統計學差異（ P均＜0.05），而治療12週後，兩組哮喘控製率和ACT評分無統計學差異（ P均＞0.05）；兩組患者治療療程結束時，肺功能指標FEV1、 FEV1％和PEF％均明顯改善，與治療前比較差異具有統計學意義（ P均＞0.05），但兩組間比較均無統計學的差異（ P＞0.05）。結論佈地奈德福莫特囉榦粉吸入劑與孟魯司特可在早期迅速控製哮喘癥狀，改善病情，降低複髮率，兩藥聯閤使用具有獨特的優越性。
목적：포지내덕복막특라간분흡입제연합맹로사특대중중도지기관효천폐공능적영향。방법선취아원85례중중도지기관효천，수궤분위관찰조45례，대조조40례。량조환자출현증상시사용단효지기관서장제완해증상，대조조급여포지내덕/복막특라간분흡입제（160μg/4.5μg/흡，아사리강공사，조만각1흡），관찰조재대조조기출상구복맹로사특（10 mg，묵사동공사，1천1편）치료，료정12 w，비교량조치료전、치료후4、8、12 w적림상공제효과화폐공능적변화。결과치료전，량조ACT평분화기본공제솔무통계학차이（ P균＞0.05），치료후4 w화8 w후，관찰조적효천증상기본공제솔분별위91.11％화93.33％， ACT평분분별위23.17±4.87화25.31±3.61，균현저고우대조조，량조비교구유통계학차이（ P균＜0.05），이치료12주후，량조효천공제솔화ACT평분무통계학차이（ P균＞0.05）；량조환자치료료정결속시，폐공능지표FEV1、 FEV1％화PEF％균명현개선，여치료전비교차이구유통계학의의（ P균＞0.05），단량조간비교균무통계학적차이（ P＞0.05）。결론포지내덕복막특라간분흡입제여맹로사특가재조기신속공제효천증상，개선병정，강저복발솔，량약연합사용구유독특적우월성。
Objective To explore the effect on lung function of Budesonide and Fomoterol Fumarate Powder for Inhalation in combination with Montelukast in the treatment of moderate to severe bronchial asthma.Methods 85 patients with moderate and severe bronchial asthma were randomly selected and divided into observation group (45 cases) and control group (40 cases).Patients in the observation group received Budesonide and Fomoterol Fumarate Powder for Inhalation in combination with Montelukast (10 mg, MRK, once daily), while the control group received the Budesonide and Fomoterol Fumarate Powder for Inhalation only (160 μg/4.5 μg/snuff, AZN, twice daily), 12 weeks for each treatment.The clinical control effect and lung function were compared between the two groups before and after treatment in the 4, 8 and 12 weeks.Results There were no significant differences in control rate and ACT scores in the two groups before treatment (P>0.05).The control rate of observation group after 4 and 8 weeks is 91.11%and 93. 33%respectively, and the ACT scores are 23.17±4.87 and 25.31±3.61 respectively, which are significantly higher than those of the control group.There were significant differences in the two groups (P<0.05).There were no significant differencesafter 12 weeks of treatment (P>0.05).By the end of the course, there had been significant differences in FEV1, FEV1% and PEF% compared with the prior treatment ( P>0.05 ) , but there were no significant differences in the two groups ( P>0.05 ) .Conclusion Budesonide and Fomoterol Fumarate Powder for Inhalation in combination with Montelukast, with the unique advantages, prove to be obviously effective in controlling asthma in the early stage, improving the symptoms and reducing the recurrence rate.
